National Heart Lung and Blood Institute Grants

Open National Heart Lung and Blood Institute grants

• COPD GENE - GENETIC EPIDEMIOLOGY OF COPD - TASK AREA A: YEAR 3 - AUGUST 10, 2025 - AUGUST 9, 2026

  Up to $9.3MDeadline: Aug 9, 2026open

  Genetic Epidemiology of COPD (COPDGene) is a multi-site longitudinal cohort study of current and former smokers to better understand risk factors, nat...

• Impact of Asymptomatic CMV on Cardiovascular Event Risk in Treated HIV

  Up to $3.0MDeadline: Jul 31, 2029open

  People with HIV (PWH) remain at higher risk for Type 1 myocardial infarction (T1MI), ischemic stroke, and venous thromboembolism (VTE) than the genera...

• Optimizing HCT Outcomes: A Multi-omic Investigation

  Up to $2.0MDeadline: May 31, 2030open

  Hematopoietic stem cell transplantation (HCT) is an essential treatment for high-risk non-malignant and malignant hematologic diseases. However, outco...

• 1/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)

  Up to $2.0MDeadline: Jul 31, 2026open

  Pulmonary arterial hypertension (PAH) is a disease of progressive obliteration of the lung vasculature that results from elastase mediated degradation...

• A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung Diseases

  Up to $2.0MDeadline: Jul 31, 2027open

  Muco-obstructive lung diseases, e.g., COPD, asthma, CF, and PCD, cause major health problems to many citizens of the US. Recent CT data have identifie...

• Optimized development of novel leaflet biomaterials for replacement heart valves

  Up to $1.4MDeadline: May 31, 2029open

  The ideal replacement heart valve (RHV) should have sufficient durability, resistance to thrombosis, and excellent hemodynamics that lasts the remaini...

• iPRISM (Imaging-enhanced Prediction of RIsk for Sudden cardiac death in hcM)

  Up to $1.3MDeadline: May 31, 2029open

  Hypertrophic cardiomyopathy (HCM) is an inherited heart condition where the heart is thicker than normal. It is an inheritable genetic condition and t...

• Molecular and Translational Studies in Hematologic Disorders

  Up to $1.3MDeadline: Feb 28, 2032open

  This application for an NHLBI R35 Outstanding Investigator Award is to continue R35-funded studies on mech- anism of disease in von Willebrand Disease...

• Precision Circadian Medicine for Shift Workers in the Digital Era

  Up to $1.1MDeadline: Mar 31, 2033open

  /Abstract All essential 24-hr operations (e.g., first responders, hospital services) rely on nightshift workers who forgo nocturnal sleep for work. Th...

• Estrogen signaling in chronic asthma

  Up to $1.0MDeadline: Jul 31, 2027open

  Epidemiological data show increased incidence and severity of asthma in women, which likely reflects both inherent sex differences and importantly the...

• Development of a Totally Implanted Left Ventricular Assist Device

  Up to $1.0MDeadline: Feb 29, 2028open

  /Abstract In the United States (US) ~6.5 million people have heart failure (HF), there are ~1 million new cases each year, and ~250,000 patients die o...

• 2/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)

  Up to $937KDeadline: Jul 31, 2030open

  The ATHENA trial represents a new paradigm to slowing the progression of disease in people with pulmonary arterial hypertension (PAH). With our clinic...

• Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome

  Up to $887KDeadline: Feb 28, 2028open

  /ABSTRACT CMTx Biotech is a drug development company working to rescue, develop and commercialize a proprietary clinical-stage drug candidate, incycli...

• Application of Modern Methods to Predict Risk and Estimate Treatment Effectiveness in Cardiogenic Shock

  Up to $817KDeadline: May 31, 2029open

  /ABSTRACT Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) is a major driver of global morbidity and mortality. Due to the chall...

• Optimizing Medications and Lung Health in People with HIV through Pharmacist-led Proactive E-Consults (OPTIMIZE Lung-HIV)

  Up to $804KDeadline: May 31, 2030open

  /ABSTRACT Despite effective antiretroviral therapy (ART) for people with HIV (PWH), community acquired pneumonia remains a common cause of hospitaliza...

• RBC-bound cell-free DNA as a predictor of acute anemia in sickle cell disease

  Up to $798KDeadline: Feb 28, 2031open

  /Abstract Sickle cell disease (SCD) is characterized by a chronic, relatively stable anemia that is punctuated by acute drops in hemoglobin. These acu...

• Incorporating Donor Lung CT Images into Machine Learning Models to Predict Severe Primary Graft Dysfunction after Lung Transplantation

  Up to $782KDeadline: May 31, 2029open

  /ABSTRACT Primary graft dysfunction (PGD) is a form of acute lung injury that occurs in the first 72 hours after lung transplantation. PGD is the lead...

• Unraveling The Mechanism of Heart Failure in Hypertrophic Cardiomyopathy with Exercise CMR

  Up to $777KDeadline: Jan 31, 2030open

  Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, with heart failure (HF) being the most common adverse complication and cau...

• Endothelial protocadherins in vascular development and disease

  Up to $776KDeadline: May 31, 2029open

  Transcription factors Klf2 and 4 are strongly induced in vascular endothelial cells (ECs) by fluid shear stress from blood flow, where they confer vas...

• Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea (CALM-OSA).

  Up to $765KDeadline: May 31, 2030open

  New approaches to understanding the mechanisms of treatments for obstructive sleep apnea (OSA) are desperately needed. OSA affects fifty-four million ...

Where National Heart Lung and Blood Institute grants go

Recent grant recipients are concentrated in these states. Funders sometimes fund outside their primary states for high-fit projects, so don't self-eliminate solely on geography — check each opportunity's stated eligibility.

How to apply for National Heart Lung and Blood Institute grants

Most National Heart Lung and Blood Institute applications require: an organizational profile with mission and programs, a project proposal aligned with the funder's stated priorities, a project budget, and supporting attachments (IRS determination letter, board list, recent financials). Federal applicants additionally need a SAM.gov UEI and an active Grants.gov account.